We develop drug candidates to advance into the clinic with pharmaceutical partners
We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities.
Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.
Our pipeline
We are inviting pharmaceutical partners to take all current and future candidates to clinical success.
Indication
C3 glomerulopathy (C3G)
Complement disorders
Complement disorders
Research
Preclinical
Phase I
Phase II
Compleva FH /CPV-101 (natural complement regulator)
Indication C3 glomerulopathy (C3G)
Compleva FH /CPV-101
(natural complement regulator)
Research
Preclinical
Phase I
Phase II
Indication Complement disorders
Compleva MFHR1/CPV-102
(novel multi-level complement regulator)
Research
Preclinical
Phase I
Phase II
Indication Complement disorders
Compleva FHL/CPV-103
(natural complement regulator)
Research
Preclinical
Phase I
Phase II
Fabry disease
Pompe disease
Repleva GAA/RPV-002 (glyco-improved Pompe-ERT)
Indication Fabry disease
Repleva AGAL/RPV-001Â
(glyco-improved Fabry-ERT)
Research
Preclinical
Phase I
Phase II
Indication Pompe disease
Repleva GAA/RPV-002
(glyco-improved Pompe-ERT)
Research
Preclinical
Phase I
Phase II
Research
Preclinical
Phase I
Phase II